Skip to main content
Equibles
AMRX logo

AMRX · Amneal Pharmaceuticals, Inc. · Metrics

Track AMRX — free

Use AMRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.20 +0.00 (+0.00%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$6.45B
Shares
319.35M
Volume · Oct 21 4.66M Avg daily vol (3M) 2.56M

AMRX metrics

105 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.20
Market cap
$6.45B

Price action

20 metrics
Price change (1W)
+6.9%
Price change (30D)
+3.6%
Price change (3M)
+13.8%
Price change (6M)
+57.6%
Price change (YTD)
+60.3%
Price change (1Y)
+96.3%
Trailing year
Price change (5Y)
+253.1%
52-week high
$20.50
52-week low
$10.00
Change from 52-week high
-1.5%
Change from 52-week low
+102.0%
Annualized volatility
35.9%
Annualized volatility (3M)
38.7%
Beta
0.6
RSI (14D)
59.8
Price vs SMA 50
+8.1%
Price vs SMA 200
+30.6%
Avg volume (3M)
2.56M
Relative volume
1.8
Average dollar volume
$48.49M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
319.35M

Valuation

12 metrics
P / E (TTM)
42.1
Trailing earnings · reciprocal yield 2.4%
PEG ratio
0.3
EV / revenue
2.9×
reciprocal yield 35.1%
EV / EBITDA
—
EV / EBIT
19.6×
reciprocal yield 5.1%
P / sales
2.1×
reciprocal yield 48.4%
P / book
195.2
reciprocal yield 0.5%
FCF yield
2.0%
TTM · current market cap
Buyback yield
—
P / FCF
50.4
reciprocal yield 2.0%
P / operating cash flow
32.1
reciprocal yield 3.1%
Earnings yield
2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
268.4×
reciprocal yield 0.4%
P / E historical average (5Y)
230.5×
reciprocal yield 0.4%
EV / revenue historical average (3Y)
1.9×
reciprocal yield 51.8%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 51.8%
EV / EBIT historical average (3Y)
19.4×
reciprocal yield 5.1%
EV / EBIT historical average (5Y)
19.4×
reciprocal yield 5.1%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-03
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
39.3%
Operating margin
14.6%
Trailing 12 months
Net margin
5.0%
Gross profit (TTM)
$1.23B
Operating profit (TTM)
$453.92M
Net income (TTM)
$157.36M
Trailing 12 months
Diluted EPS (TTM)
$0.48
FCF margin
4.1%
Effective tax rate
-7.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$9.52
Gross profit per diluted share (TTM)
$3.74
Operating profit per diluted share (TTM)
$1.38
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$0.48
Operating cash flow per diluted share (TTM)
$0.62
Free cash flow per diluted share (TTM)
$0.39
Capital expenditures per diluted share (TTM)
$0.22
R&D per diluted share (TTM)
$0.54
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
+9.9%
Year over year
Net income growth YoY
+157.2%
Revenue (TTM)
$3.12B
Trailing 12 months
EPS growth YoY
+157.1%
Shares change YoY
+1.8%
Year over year · more shares
Revenue CAGR (3Y)
+10.9%
Revenue CAGR (5Y)
+8.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-18.5%
FCF CAGR (3Y)
+143.5%
FCF CAGR (5Y)
-3.5%

Quality

14 metrics
Return on equity
476.5%
Return on assets
4.2%
Debt / equity
77.8
Current ratio
2.2
EBITDA (TTM)
—
Free cash flow (TTM)
$127.83M
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$2.44B
Latest balance sheet
Cash & equivalents
$127.64M
Total assets
$3.78B
Total debt
$2.57B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$200.78M
Capital expenditures (TTM)
$72.94M
R&D (TTM)
$175.57M
SG&A (TTM)
$571.86M
Stock compensation (TTM)
$35.63M
R&D / revenue
5.6%
Stock compensation / revenue
1.1%

Ownership (13F)

9 metrics
13F filers
313
13F filer change QoQ
-6
Institutional ownership
51.2%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
11.2%
Private-fund adviser ownership
10.0%
Active holders' share change QoQ
-1.2%
Holder tenure
14.1
Price vs estimated holder cost
+98.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.6%

Short interest

3 metrics
Short interest
3.5%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7.22M
Insider-sentiment score
13 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1723128 CUSIP 03168L105 13F (30d) 54 filings 50 filers Visit website Investor relations